World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 3 September 2018
Main ID:  EUCTR2018-002579-16-SE
Date of registration: 16/07/2018
Prospective Registration: Yes
Primary sponsor: Karolinska University Hospital, Stockholm CF center
Public title: Measurement of the posaconazole concentration in exhaled breath in CF patients after a single dose posaconazole to correlate to the concentration in blood and saliva.
Scientific title: Evaluation of the possible use of analysis of posaconazole in exhaled breath as a surrogate marker for the lung to monitor adequate dosages of posaconazole in CF patients treated for Aspergillus spp. related lung-disease. Part 1. Pharmacokinetic single center study.
Date of first enrolment: 26/08/2018
Target sample size: 12
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002579-16
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Sweden
Contacts
Name: Lena Hjelte   
Address:  Karolinska Univerisitetssjukhuset, Kirurgivägen 56-58 14186 Stockholm Sweden
Telephone: +4672560 36 32
Email: lena.hjelte@sll.se
Affiliation:  Karolinska University Hospital, Stockholm CF center
Name: Lena Hjelte   
Address:  Karolinska Univerisitetssjukhuset, Kirurgivägen 56-58 14186 Stockholm Sweden
Telephone: +4672560 36 32
Email: lena.hjelte@sll.se
Affiliation:  Karolinska University Hospital, Stockholm CF center
Key inclusion & exclusion criteria
Inclusion criteria:
1. Confirmed diagnosis of cystic fibrosis
2. = 18 and < 65 years of age
3. Males and females
4. Clinically stable disease (but different pulmonary status)
5. Willing to participate in the study
6. Willing to use contraceptives
7. Signed informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 12
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Previous adverse event on posaconazole
2. Ongoing treatment with posaconazol.
3. Advanced liver disease
4. Prolonged QTc-interval
5. Pregnancy, breastfeeding
6. Ongoing upper or lower respiratory infection requiring antibiotic treatment
7. Ongoing treatment with compounds contraindicated according to FASS
8. Ongoing or previous participation in a clinical pharmaceutical study within 28-days before screening.
9. Investigator assesses that it is not an appropriate study for the patient




Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Cystic Fibrosis (CF) is the most common life–limiting autosomal recessive disease among people of European heritage. The condition is a result of a mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene on chromosome seven, which encodes a chloride channel. In the lung defective channel activity leads to thick, viscous secretion and impaired mucociliary clearance. This causes trapping of mucus, colonization with bacteria and fungi, and a persistent inflammatory response.
MedDRA version: 20.0 Level: PT Classification code 10074549 Term: Cystic fibrosis respiratory infection suppression System Organ Class: 10042613 - Surgical and medical procedures
Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Intervention(s)

Trade Name: Noxafil®
Pharmaceutical Form: Tablet

Primary Outcome(s)
Main Objective: To study the pharmacokinetic of posaconazole in exhaled breath.
Primary end point(s): Concentration of posaconazol in exhaled breath at different time points.
Secondary Objective: To assess how the concentration of posaconazol in exhaled breath relates to that in serum and saliva.
To assess if there is a correlation between concentration of posaconazol in exhaled breath and pulmonary changes.

Timepoint(s) of evaluation of this end point: 0.5, 1, 1.5, 2, 3, 4, 8, 11, 24, 32, and 48 h after dosing.
Secondary Outcome(s)
Secondary end point(s): Concentration of of posaconazol in serum and saliva.
Pulmonary changes measured by pulmonary function (FEV1) and pulmonary structural changes measured by existing HRCT.
Timepoint(s) of evaluation of this end point: 0.5, 1, 1.5, 2, 3, 4, 8, 11, 24, 32, and 48 h after dosing.
Secondary ID(s)
CF001
Source(s) of Monetary Support
Karolinska University Hospital, Stockholm CF center
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history